Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression pro-filing study

被引:150
作者
Gong, Yun
Yan, Kai
Lin, Feng
Anderson, Keith
Sotiriou, Christos
Andre, Fabrice
Holmes, Frankie A.
Valero, Vicente
Booser, Daniel
Pippen, John E., Jr.
Vukelja, Svetislava
Gomez, Henry
Mejia, Jaime
Barajas, Luis J.
Hess, Kenneth R.
Sneige, Nour
Hortobagyi, Gabriel N.
Pusztai, Lajos
Symmans, W. Fraser
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Inst Jules Bordet, B-1000 Brussels, Belgium
[5] Inst Gustave Roussy, Villejuif, France
[6] US Oncol Texas Oncol, Houston, TX USA
[7] US Oncol Texas Oncol, Sammons Canc, Dallas, TX USA
[8] US Oncol Texas Oncol, Tyler Canc, Tyler, TX USA
[9] Natl Inst Neoplast Dis, Dept Med, Lima, Peru
[10] Mexican Inst Social Secur, Dept Ginecol Oncol, Guadalajara, Jalisco, Mexico
关键词
D O I
10.1016/S1470-2045(07)70042-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Gene expression microarrays are being used to develop new prognostic and predictive tests for breast cancer, and might be used at the same time to confirm oestrogen-receptor status and ERBB2 status. Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling. Methods We used gene expression data of 495 breast cancer samples to assess the correlation between oestrogen receptor (ESR1) and ERBB2 mRNA and clinical status of these genes (as established by immunohistochemical [IHC] or fluorescence in-situ hybridisation [FISH], or both). Data from 195 fine-needle aspiration (FNA) samples were used to define mRNA cutoff values that assign receptor status. We assessed the accuracy of these cutoffs in two independent datasets: 123 FNA samples and 177 tissue samples (ie, resected or core-needle biopsied tissues). Profiling was done at two institutions by use of the same platform (Affymetrix U133A GeneChip). All data were uniformly normalised with WHIP software. Findings ESR1 and ERBB2 mRNA levels correlated closely with routine measurements for receptor status in all three datasets. Spearman's correlation coefficients ranged from 0.62 to 0.77. An ESR1 mRNA cutoff value of 500 identified oestrogen-receptor-positive status with an overall accuracy of 90% (training set), 88% (first validation set), and 96% (second validation set). An ERBB2 mRNA threshold of 1150 identified ERBB2-positive status with the overall accuracy of 93% (training set), 89% (first validation set), and 90% (second validation set). Reproducibility of mRNA measurements in 34 replicate experiments was high (correlation coefficient 0.975 for ESR1, 0.984 for ERBB2). Interpretation Amounts of ESR1 and ERBB2 mRNA as measured by the Affymetrix GeneChip reliably and reproducibly establish oestrogen-receptor status and ERBB2 status, respectively.
引用
收藏
页码:203 / 211
页数:9
相关论文
共 35 条
  • [1] *AFF, GENECHIP EXPR AN TEC
  • [2] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
    Bonneterre, J
    Thürlimann, B
    Robertson, JFR
    Krzakowski, M
    Mauriac, L
    Koralewski, P
    Vergote, I
    Webster, A
    Steinberg, M
    von Euler, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) : 3748 - 3757
  • [3] Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Buyse, Marc
    Loi, Sherene
    van't Veer, Laura
    Viale, Giuseppe
    Delorenzi, Mauro
    Glas, Annuska M.
    d'Assignies, Mahasti Saghatchian
    Bergh, Jonas
    Lidereau, Rosette
    Ellis, Paul
    Harris, Adrian
    Bogaerts, Jan
    Therasse, Patrick
    Floore, Arno
    Amakrane, Mohamed
    Piette, Fanny
    Rutgers, Emiel
    Sotiriou, Christos
    Cardoso, Fatima
    Piccart, Martine J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17): : 1183 - 1192
  • [4] Evaluation of DNA microarray results with quantitative gene expression platforms
    Canales, Roger D.
    Luo, Yuling
    Willey, James C.
    Austermiller, Bradley
    Barbacioru, Catalin C.
    Boysen, Cecilie
    Hunkapiller, Kathryn
    Jensen, Roderick V.
    Knight, Charles R.
    Lee, Kathleen Y.
    Ma, Yunqing
    Maqsodi, Botoul
    Papallo, Adam
    Peters, Elizabeth Herness
    Poulter, Karen
    Ruppel, Patricia L.
    Samaha, Raymond R.
    Shi, Leming
    Yang, Wen
    Zhang, Lu
    Goodsaid, Federico M.
    [J]. NATURE BIOTECHNOLOGY, 2006, 24 (09) : 1115 - 1122
  • [5] *DCHIP, DCHIP SOFTW GEN EXPR
  • [6] Impact of microarray data quality on genomic data submissions to the FDA
    Frueh, Felix W.
    [J]. NATURE BIOTECHNOLOGY, 2006, 24 (09) : 1105 - 1107
  • [7] Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma
    Gong, Y
    Symmans, WF
    Krishnamurthy, S
    Patel, S
    Sneige, N
    [J]. CANCER CYTOPATHOLOGY, 2004, 102 (01) : 34 - 40
  • [8] Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
    Harvey, JM
    Clark, GM
    Osborne, CK
    Allred, DC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1474 - 1481
  • [9] Gene-expression profiles in hereditary breast cancer.
    Hedenfalk, I
    Duggan, D
    Chen, YD
    Radmacher, M
    Bittner, M
    Simon, R
    Meltzer, P
    Gusterson, B
    Esteller, M
    Kallioniemi, OP
    Wilfond, B
    Borg, Å
    Trent, J
    Raffeld, M
    Yakhini, Z
    Ben-Dor, A
    Dougherty, E
    Kononen, J
    Bubendorf, L
    Fehrle, W
    Pittaluga, S
    Gruvberger, S
    Loman, N
    Johannsoson, O
    Olsson, H
    Sauter, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (08) : 539 - 548
  • [10] Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Hess, Kenneth R.
    Anderson, Keith
    Symmans, W. Fraser
    Valero, Vicente
    Ibrahim, Nuhad
    Mejia, Jaime A.
    Booser, Daniel
    Theriault, Richard L.
    Buzdar, Aman U.
    Dempsey, Peter J.
    Rouzier, Roman
    Sneige, Nour
    Ross, Jeffrey S.
    Vidaurre, Tatiana
    Gomez, Henry L.
    Hortobagyi, Gabriel N.
    Pusztai, Lajos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) : 4236 - 4244